Technology and innovation watch
Share
Teva Pharmaceutical’s business strategy in the United States is based largely on selling generic versions of blockbuster drugs even though the company is liable to lose patent infringement suits filed subsequently by the makers of the propriety versions. Teva assumes a calculated risk that it will lose these cases, and [...]
ShareLONDON -(Dow Jones)- U.K. drug maker Shire PLC (SHP.LN) Friday said its U.S. subsidiary filed a lawsuit there against Teva Pharmaceutical Industries Ltd. ( TEVA), alleging that the Israel-based generic drugs maker infringed two patents for Shire’s hyperactivity medicine Intuniv.
Shire, the U.K.’s third-largest drug company, said its lawsuit results from an [...]
Share
NEW YORK — French drugmaker
Sanofi-Aventis ( SNY - news - people ) said it resolved lawsuits against Hospira ( HSP - news - people ) Inc.’s Mayne Pharma unit, Turkish drugmaker MN Pharmaceuticals and Actavis Inc. Each company was selling a generic version of Sanofi-Aventis’ Eloxatin, but under the settlement, they will stop selling the drug on June 30 and not resume until Aug. 9, 2012.
Sanofi-Aventis said Tuesday it [...]
ShareIndian pharma firms seem to be in an upbeat mood as far as strengthening their presence in the US via the patent litigation route is concerned. This year, from January 2010 till date, Indian pharma majors, such as Lupin, Sun Pharma and Aurobindo, have entered into about 11 litigations with various patent-holding MNCs. Lupin leads [...]